

# Resource Summary Report

Generated by [kravitz2](#) on Aug 9, 2026

## Tempus

RRID:SCR\_025832

Type: Tool

### Proper Citation

Tempus (RRID:SCR\_025832)

### Resource Information

**URL:**

<https://www.tempus.com/?srsltid=AfmBOooE0mE1FASi3ABHLngEKJRPI0MVlxiInUqW4nFn5OVm8>

**Proper Citation:** Tempus (RRID:SCR\_025832)

**Description:** Biotechnology company that specializes in collection and analysis of molecular and clinical data to advance precision medicine.

**Resource Type:** commercial organization

**Keywords:** molecular and clinical data collection, precision medicine,

**Resource Name:** Tempus

**Resource ID:** SCR\_025832

**Record Creation Time:** 20241002T053256+0000

**Record Last Update:** 20260808T190733+0000

### Ratings and Alerts

No rating or validation information has been found for Tempus.

No alerts have been found for Tempus.

### Data and Source Information

**Source:** [SciCrunch Registry](#)

### Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Lee LH, et al. (2025) Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. Cancer research communications, 5(6), 1049.

von Itzstein MS, et al. (2025) Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(4), 639.

Rao X, et al. (2023) Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3372.